Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

HealthFusion’s MediTouch?? EHR Ranked As Top 3 For Clinical Quality And Support In Medical Economics’ National Provider Survey

October 20, 2014 – 5:00 am | Edit Post

SOLANA BEACH, Calif., Oct. 20, 2014 /PRNewswire/ — HealthFusion, maker of MediTouch EHR, the leading cloud computing software for physicians, hospitals, and medical billing services, was ranked as a Top 3 Electronic Health Record (EHR…

As Apple, Offer Egg Freezing, Debate Swirls

October 20, 2014 – 5:00 am | Edit Post

Thermo Fisher Scientific Release: New Digital PCR-Based Research Solution Characterizes Hard-To-Detect Cancer Mutations

October 20, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific announced today the release of the QuantStudio 3D Rare Mutation Analysis Solution, a panel of wet-lab validated assays combined with an enhanced software tool that enables researchers to detect and quantify 40 of the most common mutations in cancer genes at a prevalence as low as 0.1 percent.Tumor heterogeneity presents a significant…

RainDance Technologies Showcases Leading Genomic Researchers And Novel Sequencing Solutions At American Society of Human Genetics Annual Meeting

October 20, 2014 – 5:00 am | Edit Post

RainDance Technologies, Inc., a genomics tools company simplifying the analysis of complex genetics, today announced the speaker lineup for its upcoming customer workshop at the American Society of Human Genetics (ASHG) Annual Meeting taking place in San Diego, California Oct 18-22, 2014. RainDance will showcase its complete line of products enabling novel, non-invasive Fluid Biopsy applications for…

Halozyme Therapeutics, Inc. Receives FDA Approval For Additional Manufacturing Facilities For Hylenex?? Recombinant

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing facilities used in the production of Hylenexrecombinant (hyaluronidase human injection). The FDA approved…

Lpath, Inc. Granted Key European Patent Related To iSONEP And ASONEP Programs

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics,received official notification from the European Patent Office that the company has been granted another key patent supporting its iSONEP and ASONEP programs. This newly issued…

Lion Biotechnologies, Inc. CSO Co-Authors Study In

October 20, 2014 – 5:00 am | Edit Post

LOS ANGELES, Oct. 20, 2014 (GLOBE NEWSWIRE) — Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that research by chief scientific officer Laszlo Radvanyi, PhD, has been published…

QIAGEN N.V. Demonstrates Expanded Bioinformatics Workflows At American Society of Human Genetics; Strong Market Adoption As Researchers Analyze Genomic Data On More Than A Quarter-Million Samples In Secure Private Cloud

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO and HILDEN, Germany, October 17, 2014 /PRNewswire/ — Translational research in cancer and other diseases will benefit from new capabilities being presented at the American Society of Human Genetics annual meeting Volume of 250,000-plus DNA samples linked to Ingenuity Knowledge Base greatly exceeds any comparable database – providing superior depth for genomic…

Amicus Therapeutics, Inc. Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011

October 20, 2014 – 5:00 am | Edit Post

Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR) Additional GL-3 Data Further Validate Assay for Identifying Patients with Amenable Mutations

Affymetrix (Santa Clara, California) Exclusively Licenses Technology From For HLA Typing From Genotyping Data

October 20, 2014 – 5:00 am | Edit Post

SANTA CLARA, Calif.–(BUSINESS WIRE)–Affymetrix (NASDAQ:AFFX) announced today that it has exclusively licensed technology from Peptide Groove LLP that enables HLA typing of human samples from genotyping data generated from a variety of assays including the company’s Axiom genotyping assays. The partners at Peptide Groove LLP developed HLA*IMP, the first HLA typing statistical imputation method which…